NCT02874742 – Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma Posted on October 28, 2024 by Molly Willeford -
NCT00574288 – Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma – Open Label, Dose-escalation Followed by Open Label, Single-arm Study Posted on August 5, 2023 by tsuperadmin -
NCT04021862 – A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Atopic Dermatitis Posted on August 5, 2023 by tsuperadmin -
NCT03277105 – A Phase 3 Randomized, Multicenter Study of Subcutaneous vs. Intravenous Administration of Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Posted on August 5, 2023 by tsuperadmin -
NCT03412565 – A Multicenter Phase 2 Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens Posted on August 5, 2023 by tsuperadmin -
NCT01998971 – An Open-Label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Regimens for the Treatment of Subjects With Multiple Myeloma Posted on August 5, 2023 by tsuperadmin -
NCT02951819 – Daratumumab Plus Cyclophosphamide, Bortezomib and Dexamethasone (Dara-CyBorD) in Previously Untreated and Relapsed Subjects With Multiple Myeloma Posted on August 5, 2023 by tsuperadmin -
NCT04019041 – A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Bermekimab in Patients With Moderate to Severe Hidradenitis Suppurativa Posted on August 5, 2023 by tsuperadmin -
NCT02195479 – A Phase 3, Randomized, Controlled, Open-label Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High-dose Therapy Posted on April 26, 2022 by tsuperadmin -
NCT03180736 – A Phase 3 Study Comparing Pomalidomide and Dexamethasone With or Without Daratumumab in Subjects With Relapsed or Refractory Multiple Myeloma Who Have Received at Least One Prior Line of Therapy With Both Lenalidomide and a Proteasome Inhibitor Posted on April 26, 2022 by tsuperadmin -
The YODA Project